Coya Therapeutics, Inc. (COYA)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $2.99
- As of
Kresmion compiles this page from COYA's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Coya Therapeutics, Inc. (COYA): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-14.
See the full COYA dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for COYA on one page. Preview it with sample data, then open it live with a free account.
Preview the COYA dossierActive events for COYA
- mediumEarnings above estimates
Q2-2026: Beat consensus by 19.3%, EPS $-0.28 vs $-0.3468 estimate
- high13F: large increase
RENAISSANCE TECHNOLOGIES LLC added +86% to COYA (2026Q2)
- high13F: large increase
RENAISSANCE TECHNOLOGIES LLC added +55% to COYA (2026Q1)
- mediumEarnings above estimates
Q2-2025: Beat consensus by 10.2% - EPS $-0.36 vs $-0.4007 estimate
- mediumEarnings above estimates
Q3-2025: Beat consensus by 53.4% - EPS $-0.13 vs $-0.2788 estimate
FREE, NO ACCOUNT
Every event on COYA, as it fires
You are seeing 5 of 7 events recorded on COYA since 2026-05-31.
The five above landed across 4 days. The other 2 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
COYA positions held by the managers we follow (2026Q2)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC FundCUSIP 22407B108 · 2026Q2 | $1.1M | 0.00% |
| CITADEL ADVISORS LLC FundCUSIP 22407B108 · 2026Q2 | $77K | 0.00% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, COYA
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
More data on COYA
COYA mentioned in Kresmion daily briefs
COYA against its peers
COYA's operating margin of -283.9% ranks in the 50th percentile of 10 Biotechnology sub-industry peers, fiscal periods ending between 2025-03-31 and 2026-04-30.
| Metric | COYA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 7.9M USD | 3.6M USD | 54 | 11 |
| Operating margin | -283.9% | -285.8% | 50 | 10 |
| Net margin | -267.1% | -285.0% | 50 | 10 |
| Return on equity | -49.3% | -59.0% | 69 | 17 |
Peers (22): MAIA, CSBR, NTRB, TENX, GOSS, KLRS, CGTX, MNOV, CRBP, SMNR, CRDF, FBIO, ACRV, CING, RANI, SPRO, OKYO, ONCY, XBIT, BOLD, NRXS, ATRA. Left out: TELO (no annual filing), CNXU (no annual filing), APLM (period gap). Fiscal periods ending between 2025-03-31 and 2026-04-30. Every figure is one full fiscal year read from one annual filing (COYA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in COYA on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on COYA in the last 180 days.
Upstream: SEC EDGAR filings for COYA
Kresmion, "Coya Therapeutics, Inc. (COYA) institutional holdings and SEC filings", data as of 2026-10-14, https://kresmion.com/research/COYA. Upstream data: SEC EDGAR filings for COYA.
Link to this data (HTML):
<a href="https://kresmion.com/research/COYA">Coya Therapeutics, Inc. (COYA) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow COYA on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to COYA for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.